Le Lézard
Classified in: Ebola virus, Health
Subject: SVY

Global Automated and Rapid Microbiological Tests - Biotechnology


NEW YORK, Feb. 20, 2017 /PRNewswire/ -- rt analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Thousand by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Read the full report: http://www.reportlinker.com/p04707098-summary/view-report.html


Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 83 companies including many key and niche players such as:
- Abbott Laboratories
- Alere Inc.
- Beckman Coulter, Inc.
- Becton Dickinson and Company
- bioMérieux SA


Read the full report: http://www.reportlinker.com/p04707098-summary/view-report.html

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Clinical Applications..............I-4 Automated Identification and Susceptibility Systems I-4 Automated Blood Culture Systems I-4 Automated Tuberculosis Systems I-4 Streptococcal Infection Rapid Tests I-4 GC/Chlamydia Rapid Tests..............I-5 Other Automated & Rapid Microbiological Tests I-5 Non-Clinical Applications..............I-5

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 Global In-Vitro Diagnostics Market II-1 Table 1: Global In-Vitro Diagnostics (IVD) Market by Geographic Region (2015): Percentage Share Breakdown of Revenues for the US, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World (includes corresponding Graph/Chart).............. II-1 Central Laboratories Dominate the Market II-1 Table 2: Global In-Vitro Diagnostics Market by Sector (2015): Percentage Breakdown of Revenues for Hospital & Central Laboratories, Decentralized & Patient Self-Testing (includes corresponding Graph/Chart) II-2 Immunochemistry - the Leading Segment II-2 Table 3: Global In-Vitro Diagnostics Market by Segment (2015): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Others (includes corresponding Graph/Chart)..............II-2

Table 4: Global In-Vitro Diagnostics Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Roche, Siemens, Abbott, Danaher, Thermo Fisher Scientific, Becton Dickinson, Alere, Sysmex, bioMérieux, Ortho Clinical Diagnostics, and Others (includes corresponding Graph/Chart) II-3 Automated and Rapid Microbiological Tests Revolutionize Microbiological Testing..............II-4 Evolutionary Battle against Microbes Drives Market Future II-5 Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market..............II-5 Instant Detection of Pathogens - A New Epoch in the Fight for Survival.............. II-6 Traditional Rapid Microbiological Tests Make Way for New, Probe Tests.............. II-7 Emerging Markets Provide Tremendous Growth Opportunities II-7 Clinical Applications..............II-8 Table 5: Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Region: (2016) (includes corresponding Graph/Chart)..............II-9

Table 6: Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Segment: (2016) (includes corresponding Graph/Chart)..............II-10 Non-Clinical Applications..............II-10 Table 7: Global Automated and Rapid Microbiological Tests Market in Non-Clinical Applications by Region: (2016) (includes corresponding Graph/Chart) II-11 A Holistic Peek into a Few Noteworthy Trends II-11 The Evolution of Biotechnology - A Crucial Step Ahead in the Growing Popularity of Rapid Microbial Tests II-12 Point-of-Care Rapid Microbiological Testing: Yet to Realize Its Full Potential.............. II-13

2. COMPETITION.............. II-14 Table 8: Global Microorganism Identification and Resistance Tests Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for bioMérieux, Becton Dickinson, Thermo Fisher, Beckman Coulter, Others (includes corresponding Graph/Chart).............. II-14

Table 9: Global Blood Screening Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Roche and Others (includes corresponding Graph/Chart) II-14

Table 10: Global GC-CT Testing Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Becton Dickinson, Roche, Qiagen NV, and Others (includes corresponding Graph/Chart) II-15 Competitive Dynamics in the C. Difficile Testing Market II-15 Table 11: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2015): Percentage Breakdown of Revenues for Cepheid, Meridian, Becton Dickinson, and Others (includes corresponding Graph/Chart) II-15 List of Select Molecular C. difficile Test Products II-16

3. MARKET DRIVERS AND TRENDS..............II-17 Increasing Incidence of Infectious Diseases - An Opportunity Indicator.............. II-17 Rising Healthcare Needs of Aging Global Population - A Growth Driver.............. II-18 Table 12: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)..............II-18

Table 13: Global Population Statistics for 65+ Age Group (2014) (includes corresponding Graph/Chart) II-19

Table 14: Aged Population (65+ Years) as a Percentage of the Total Population by Region: 2000 Vis-a-vis 2025 (includes corresponding Graph/Chart)..............II-20 The World is Ageing.............. II-20 Table 15: Elderly Population (65+ Years) as a Percentage of the Total Population: 2014 & 2025 (includes corresponding Graph/Chart).............. II-21 Rising HIV Prevalence - A Key Opportunity Indicator II-21 Some Significant HIV Statistics by Region: 2015 II-22 Table 16: Global Prevalence of HIV Infection in 2015 by Region (in Millions) (includes corresponding Graph/Chart) II-23

Table 17: Newly Infected HIV Population in 2015 by Region (in Thousands) (includes corresponding Graph/Chart) II-24

Table 18: Global HIV Related Deaths in 2015 by Region (in Thousands) (includes corresponding Graph/Chart) II-25 Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease.............. II-25 Ultra-Rapid HIV-Screening Tests put up a Strong Fight against HIV-Epidemic.............. II-26 Accuracy/Reliability of Home HIV Testing: A Bone of Contention II-26 Increase in Healthcare Spending in Emerging Markets to Propel Demand.............. II-27 Table 19: Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart) II-27

Table 20: Healthcare Spending as % of GDP in Select Countries (2014) (includes corresponding Graph/Chart) II-28 Rising Emphasis on Lab Automation to Augur Well for Market Growth II-28 Greater Patient Awareness to Drive Growth II-28 Advancements in Molecular Diagnostics - A Boon II-29 Antibiotic Resistant Bacteria Throws the Spotlight on Microbial Testing..............II-29 Influenza - Boosting Rapid Test Prospects II-30 Select FDA-approved Rapid Detection Tests for Flu A&B: (2015) II-30 Automated Blood Culture Systems: The Gold Standard in the Fight against Bacteremia..............II-31 Impact of Food Scares on Rapid Microbiological Tests Market II-32 Stringent Norms Necessitate Microbial Food Safety Testing II-33 Rapid Screening Gains Preference over Traditional Food Testing Procedures.............. II-33 Conventional Testing Continues to Dominate but Rapid Tests Making Inroads.............. II-33 Leading Food Processors Resort to Rapid Microbiological Testing II-34 Food Packages of the Future Ingrained with Microbial Alert Systems.............. II-35 Poultry Industry Embraces Rapid Microbiological Testing Technologies.............. II-35 Rapid Microbiological Tests Gain Significance in the Pharma Industry.............. II-35 Key Advantages of Rapid Microbiological Tests for Pharma- In a Nutshell.............. II-36 Growth Directtm System Creates Waves in Pharmaceutical Quality Control.............. II-37

4. KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET II-38 Validation: An Imperative Prerequisite II-38 Obtaining Regulatory Approval: A Major Non-Technical Hindrance II-38 Non-Conformance to Testing Requirements: A Weighty Concern II-38 Technical and Cost Issues Impede the Uptake of Rapid Microbiological Tests in the Food Sector II-39

5. PRODUCT/TECHNOLOGY OVERVIEW..............II-40 Automated & Rapid Microbiological Tests: A Definition II-40 How Does a Rapid Test Work?..............II-40 Enabling Technologies of Automated & Rapid Microbiological Tests II-41 Growth-based Technologies..............II-41 Viability-based Technologies..............II-41 Cellular-Component or Artifact-based Technologies II-41 Genomics/Proteomics..............II-41 Microarrays/Microfluidics..............II-41 DNA Microchips/Probes..............II-42 Polymerase Chain Reaction (PCR) II-42 Immunoassay.............. II-43 Nucleic Acid Testing (NAT)..............II-43 Nucleic Acid Probes..............II-44 Signal-Amplified Tests..............II-44 Nucleic Acid Amplification Tests II-44 Traditional Methods with Computer-Aided Imaging II-45 Combination Methods..............II-45

6. APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL TESTS - A REVIEW.............. II-46 Clinical Applications..............II-46 Automated Identification and Susceptibility Systems II-46 Automated Blood Culture Systems II-46 Automated Tuberculosis Systems..............II-46 Streptococcus Infection Rapid Tests II-47 Streptococcus A Rapid Tests..............II-47 Streptococcus B Rapid Tests..............II-47 GC/Chlamydia Rapid Tests..............II-48 Other Automated & Rapid Microbiological Tests II-48 Respiratory Rapid Tests..............II-48 RSV/ Influenza Rapid Tests..............II-49 Gastrointestinal Rapid Tests II-49 Giardia Lamblia Rapid Tests II-49 H. Pylori Rapid Tests..............II-49 Cryptosporidium Rapid Tests II-50 C. Difficile Rapid Tests..............II-50 STD Rapid Tests.............. II-51 HIV Rapid Tests..............II-51 Advantages of Rapid HIV Testing II-52 Disadvantages of Rapid HIV Testing II-52 Syphilis Rapid Tests..............II-52 Applications in Non-Clinical Investigations II-52 Food/Water Safety Tests..............II-53 Food Safety Testing: A Lucrative Application Area II-53 qPCR Application in Food Microbiology: Study of Select Micro-Organisms by Target Gene and Food Substrate II-54 Rapid Microbiological Methods in Pharmaceutical Sector II-55 Limitations.............. II-55 Advantages.............. II-55 Applications in Pharmaceutical Sector II-55 Environmental Tests..............II-56 Other Miscellaneous Applications II-56

7. PRODUCT INNOVATIONS/INTRODUCTIONS II-57 bioMérieux Launches New Platform for Extraction of DNA and RNA II-57 Bio-Rad Launches IH-1000 Blood Typing System II-57 bioMérieux Launches "EviSighttm Compact" Incubator System II-57 BD Launches Next Generation Automated ID/AST System II-57 Sekisui Introduces SEKURE® TPLA and RPR Assays for Syphilis Testing.............. II-57 BD Introduces BD Veritortm Plus System II-57 Rhoenix Introduces Beer SpoilerAlerttm Assay II-57 Philips Introduces Minicare I-20 System II-57 Bio-Rad Introduces Amplichektm II Quality Control II-58 Bruker Launches Enhancements for MALDI Biotyper II-58 Thermo Fisher Launches Thermo Scientific SureTect Cronobacter Species Real-Time PCR Assay..............II-58 Hologic Introduces Aptima Mycoplasma Genitalium Assay II-58 bioMérieux and Illumina Introduce bioMérieux EpiSeqtm II-58 bioMérieux Launches GENE-UP®..............II-58 BioControl Launches Modular Automation for Assurance GDS® II-58 Rapid Micro Biosystems Launches Growth Directtm System II-58 IDEXX Launches Quanti-Tray Sealer PLUS in Europe II-59 Sekisui Introduces 3 New Assays to the OSOM Rapid Test Line II-59 Bio-Rad Launches IH-500..............II-59 bioMérieux Launches VIDAS® Lyme IgG II and VIDAS® Lyme IgM II Assays in the US.............. II-59 Meridian Introduces illumigene® HSV Assays in Europe II-59 Medicinal Genomics Introduces PathogINDICAtortm Assay II-59 Roche Introduces cobas® DPX Test II-59

8. RECENT INDUSTRY ACTIVITY..............II-60 Abbott Files for Cancellation of Acquisition Agreement with Alere II-60 Hologic Obtains CE Mark Approval for Aptima® HSV Assay II-60 Hologic Obtains Health Canada Approval for Aptima® Hepatitis C and B Quant Assays.............. II-60 Quidel Obtains FDA Approval for Solana® Assay for Various Streptococcus Strains..............II-60 Quidel Obtains FDA Approval for Solana® Assay for Influenza A&B II-60 BD Receives FDA Approval for BD MAXtm CT/GC/TV Assay II-60 OraSure Obtains BARDA Funding for Zika Tests II-61 Alere Obtains FDA Approval for Aleretm i RSV Rapid Molecular Test II-61 Magellan Diagnostics Obtains Chinese Approval for LeadCare® II II-61 Alere Receives CE Mark for Aleretm Reader II-61 Sekisui Secures Distribution Rights for FastPack® IP System from Qualigen.............. II-61 bioMérieux Submits 510(k) Application for BacT/ALERT® VIRTUOtm II-61 Alere Begins Operations at New Facility in India II-61 Alere Obtains WHO Prequalification for Aleretm HIV Combo II-61 Hologic and Grifols Receive FDA Approval for Procleix Zika Virus Assay.............. II-62 Meridian Obtains FDA Approval for illumigene® Mycoplasma Direct Assay.............. II-62 Alere Announces WHO Prequalification for Aleretm q HIV-1/2 Detect Assay.............. II-62 BD and Check-Points Enter into Development and Distribution Agreement.............. II-62 Luminex to Acquire Nanosphere..............II-62 bioMérieux Takes Over Hyglos..............II-62 BD Receives CE Mark for BD MAXtm Vaginal Panel II-62 Siemens Healthcare Changes Name to Siemens Healthineers II-62 Sekisui and Qualigen Enter into Partnership II-63 Meridian Obtains CE Mark for illumigene® Mycoplasma Direct II-63 BioFire Obtains FDA and CE Mark Approval for FilmArray® Torch use with all FilmArray® Panels..............II-63 Roche Receives FDA IND Approval for cobas® Zika Assay II-63 Meridian Takes Over Magellan Biosciences II-63 Thermo Fisher Obtains FDA Approval for B?R?A?H?M?S PCT Assay for Sepsis Risk Assessment..............II-63 BioFire Obtains FDA Approval for FilmArray® Torch for use with FilmArray® Respiratory Panel..............II-63 Abbott Signs Acquisition Agreement with Alere II-64 Siemens Receives FDA Approval for Sysmex® CS-2100i System II-64 Bio-Rad Receives FDA Approval for TANGO infinity® system II-64 Bio-Rad Obtains FDA Approval for D-100tm System for A1c Testing II-64 MedMira Obtains FDA Approval for Reveal® G4 Rapid HIV-1 Antibody Test.............. II-64 FDA Approves cobas® HBV and cobas® HCV Viral Load Tests for cobas® 6800 and cobas® 8800 Systems II-64 Hologic Obtains CE-IVD Certification for Aptima® HCV Quant Dx Assay on Panther® System..............II-64 BD and Seegene Enter into Collaboration Agreement II-65 FDA Emergency Authorization for OraSure OraQuick® Ebola Rapid Antigen Test.............. II-65 Bio-Rad Obtains Pre-Market Approval for BioPlex 2200 HIV Ag-Ab Assay.............. II-65 FDA Approves VIDAS® 3 Immunoassay from bioMérieux II-65 Meridian Obtains FDA Approval for illumigene® HSV 1&2 II-65 Charles River Laboratories Acquires Celsis International II-65 FDA Approves Quidel Solanatm Molecular System and Solanatm Molecular Assay.............. II-65 FDA Approves Roche cobas HSV 1 and 2 Test II-65 FDA Approves Roche cobas Cdiff Test II-66 MedMira Submits Supplement for FDA Approval of Reveal® G4 Rapid HIV-1 Antibody Test..............II-66 FDA Approves Aleretm i Strep A Rapid Molecular Test II-66 bioMérieux Acquires CREERAM Tools II-66 FDA Gives CLIA Waiver Aleretm i Influenza A & B Test II-66 Alere Obtains CE Mark Approval for Aleretm HIV Combo II-66 Alere Obtains IVD CE Mark Approval for Aleretm q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care II-66 FDA Gives CLIA Waiver for Aleretm i Strep A Rapid Molecular Test II-66 BioFire Obtains FDA Approval and CE-IVD Marking for FilmArray® 2.0 System.............. II-67 FDA Approves Next Generation cobas MRSA/SA Test of Roche II-67 FDA Approves cobas® TaqScreen MPX Test, v2.0 of Roche II-67 bioMérieux Signs Strategic Agreement with COPAN II-67

9. FOCUS ON SELECT GLOBAL PLAYERS..............II-68 Abbott Laboratories (US)..............II-68 Abbott Molecular, Inc. (US)..............II-68 Alere Inc. (US).............. II-69 Beckman Coulter, Inc. (US)..............II-70 Becton Dickinson and Company (US) II-70 bioMérieux SA (France)..............II-71 bioMerieux, Inc. (US)..............II-72 Bio-Rad Laboratories, Inc (US) II-72 Cellabs Pty Ltd (Australia)..............II-73 Cepheid Inc. (US).............. II-73 CorisBioconcept SPRL (Belgium) II-74 F. Hoffmann-La Roche AG (Switzerland) II-74 Hologic, Inc. (US)..............II-75 MedMira Inc. (Canada)..............II-75 Meridian Bioscience, Inc. (US) II-76 OraSure Technologies, Inc. (US)..............II-76 Orion Diagnostica Oy (Finland) II-77 QIAGEN N.V. (The Netherlands)..............II-77 Quidel Corporation (US)..............II-78 Sekisui Diagnostics, LLC (US)..............II-79 Siemens Healthcare GmbH (Germany) II-80 Thermo Fisher Scientific Inc. (US) II-80 Oxoid Limited (UK).............. II-81

10. GLOBAL MARKET PERSPECTIVE..............II-82 Table 21: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) II-82

Table 22: World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-83

Table 23: World 14-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............II-84

Table 24: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-85

Table 25: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-86

Table 26: World 14-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-87

Table 27: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) II-88

Table 28: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-89

Table 29: World 14-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Percentage Breakdown of Dollar Sales for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-90

Table 30: World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-91

Table 31: World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-92

Table 32: World 14-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-93

Table 33: World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-94

Table 34: World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-95

Table 35: World 14-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............II-96

Table 36: World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-97

Table 37: World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-98

Table 38: World 14-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............II-99

Table 39: World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-100

Table 40: World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-101

Table 41: World 14-Year Perspective for Streptococcal Infection Rapid Testsin Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-102

Table 42: World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-103

Table 43: World Historic Review for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-104

Table 44: World 14-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............II-105

Table 45: World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-106

Table 46: World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-107

Table 47: World 14-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-108

Table 48: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-109

Table 49: World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-110

Table 50: World 14-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-111

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Current & Future Analysis..............III-1 Changing Healthcare Industry Dynamics Affect Rapid and Automated Microbiological Tests Market III-1 Table 51: Healthcare Spending as a % of GDP (includes corresponding Graph/Chart) III-1 Positive Outlook for Rapid and Automated Microbiological Tests Market.............. III-2 Rapidly Ageing Demographics Drive Growth III-4 Table 52: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) III-4 Competition.............. III-5 Tracking Trends Across Product Segments III-5 Automated Identification & Susceptibility Systems III-5 Growing Popularity of FDA-Approved Automated Susceptibility Testing Equipment III-5 STD Rapid Tests..............III-6 Market Shares of Leading Players III-6 Table 53: The US Market for Syphilis Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Becton Dickinson, Alere, and Others (includes corresponding Graph/Chart)..............III-6 Gastrointestinal Rapid Tests..............III-7 Table 54: The US Market for Rotavirus Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart) III-7 Respiratory Rapid Tests..............III-7 Competition.............. III-7 Market Share Data of Leading Players III-8 Table 55: The US Market for Influenza Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Quidel, Becton Dickinson, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)..............III-8

Table 56: The US Market for RSV Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Becton Dickinson, Binax, Thermo Fisher Scientific and Others (includes corresponding Graph/Chart) III-8

Table 57: The US Market for Mononucleosis Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Alere, Oxoid, Quidel and Others (includes corresponding Graph/Chart) III-8 Streptococcus Infection Rapid Tests III-9 Table 58: The US Market for Streptococcus A Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Quidel, Thermo Fisher Scientific, Becton Dickinson, and Others (includes corresponding Graph/Chart) III-9 Testing Practices of the US Food Industry III-9 Table 59: US Food Safety Testing Market by Contaminant (2015): Percentage Breakdown of Value Sales for Pathogens, GMOs, Toxins, Residues and Others (includes corresponding Graph/Chart).............. III-10 Increasing Demand for Microbiology Tests in the Food Sector III-11 Table 60: US Microbiological Food Safety Tests by Type (2015): Percentage Share Breakdown in terms of Number of Tests for Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)..............III-11 Tackling the Burden of Food Borne Illnesses III-11 Table 61: Food-borne Illnesses, Hospitalizations and Deaths in the US (2011): Percentage Share Breakdown for Known Pathogens and Unspecified Agents (includes corresponding Graph/Chart).............. III-12

Table 62: Leading Known Pathogens Causing Food-borne Illnesses in the US (2011): Percentage Share Breakdown of Number of Illnesses by Known Pathogens - Norovirus, Salmonella nontyphoidal, Clostridium perfringens, Campylobacter spp., Staphylococcus aureus, and Others (includes corresponding Graph/Chart) III-12

Table 63: Leading Known Food-borne Pathogens Causing Hospitalizations in the US (2011): Percentage Share Breakdown of Number of Hospitalizations by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart) III-13

Table 64: Leading Known Food-borne Pathogens Causing Deaths in the US (2011): Percentage Share Breakdown of Number of Deaths by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart).............. III-13 Product Launches..............III-14 Strategic Corporate Developments III-15 Select Key Players..............III-21 B.Market Analytics..............III-30 Table 65: The US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-30

Table 66: The US Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-31

Table 67: The US 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-32

2. CANADA.............. III-33 A.Market Analysis.............. III-33 Current & Future Analysis..............III-33 Food Safety Testing in Canada..............III-33 Table 68: Canadian Food-Borne Illnesses by Category (2012): Percentage Share Breakdown of Number of Illness Caused through Known Pathogens and Unknown Pathogens (includes corresponding Graph/Chart)..............III-34

Table 69: Canadian Food-Borne Illnesses by Pathogen (2012): Percentage Breakdown of number of Illness Caused by Norovirus, Clostridium perfringers, Campylobacter spp, Salmonella spp., non-typhoidal and Others (includes corresponding Graph/Chart)..............III-34 Strategic Corporate Development III-35 Medmira Inc. - A Key Player..............III-35 B.Market Analytics..............III-36 Table 70: Canadian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-36

Table 71: Canadian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-37

Table 72: Canadian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-38

3. JAPAN.............. III-39 A.Market Analysis.............. III-39 Current & Future Analysis..............III-39 Demographics Drive Market Growth III-39 Table 73: Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)..............III-39

Table 74: Japanese 65+ Years Population Share of Total Population: 1950-2015 (includes corresponding Graph/Chart) III-40 B.Market Analytics..............III-41 Table 75: Japanese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-41

Table 76: Japanese Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-42

Table 77: Japanese 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-43

4. EUROPE.............. III-44 A.Market Analysis.............. III-44 Current & Future Analysis..............III-44 Debt Crisis in Europe Affects Healthcare Industry III-44 European Healthcare System: In a State of Transition III-44 Ageing Demography - An Opportunity Indicator III-45 Table 78: Population Breakup by Age Group for Select European Countries: 2015 (as Percentage of Total Population) (includes corresponding Graph/Chart) III-46 Clinical Vis-à-vis Non-clinical Applications III-47 What Drives the Requirement Patterns of End-Users? III-47 Proliferation of Automated, and Rapid Tests in Clinical Applications.............. III-47 Non-Clinical Applications..............III-48 Table 79: European Microbiological Food Safety Tests (2015): Percentage Share Breakdown of Number of Tests by Segment - Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)..............III-48 Strategic Corporate Developments III-48 Product Launches..............III-49 B.Market Analytics..............III-50 Table 80: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-50

Table 81: European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014(includes corresponding Graph/Chart).............. III-51

Table 82: European 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-52

Table 83: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-53

Table 84: European Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-54

Table 85: European 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-55

4a. FRANCE.............. III-56 A.Market Analysis.............. III-56 Current & Future Analysis..............III-56 Product Launches..............III-56 Strategic Corporate Developments III-57 bioMérieux SA - A Key Player III-57 B.Market Analytics..............III-59 Table 86: French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-59

Table 87: French Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-60

Table 88: French 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-61

4b. GERMANY.............. III-62 A.Market Analysis.............. III-62 Current & Future Analysis..............III-62 Food Safety - A Cause of Concern III-62 Food Safety Regulations in Germany III-62 Strategic Corporate Developments III-63 Siemens Healthcare GmbH - A Key Player III-63 B.Market Analytics..............III-64 Table 89: German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-64

Table 90: German Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-65

Table 91: German 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-66

4c. ITALY.............. III-67 A.Market Analysis.............. III-67 Current & Future Analysis..............III-67 B.Market Analytics..............III-68 Table 92: Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-68

Table 93: Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-69

Table 94: Italian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-70

4d. THE UNITED KINGDOM..............III-71 A.Market Analysis.............. III-71 Current & Future Analysis..............III-71 Non-Clinical Applications to Exhibit Fastest Growth III-71 Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics III-71 Oxoid Limited - A Key Player III-71 B.Market Analytics..............III-73 Table 95: The UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-73

Table 96: The UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-74

Table 97: The UK 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-75

4e. SPAIN.............. III-76 A.Market Analysis.............. III-76 Current & Future Analysis..............III-76 B.Market Analytics..............III-77 Table 98: Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-77

Table 99: Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-78

Table 100: Spanish 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-79

4f. RUSSIA.............. III-80 A.Market Analysis.............. III-80 Current & Future Analysis..............III-80 B.Market Analytics..............III-81 Table 101: Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-81

Table 102: Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-82

Table 103: Russian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-83

4g. REST OF EUROPE.............. III-84 A.Market Analysis.............. III-84 Current & Future Analysis..............III-84 Product Launches..............III-84 Key Players.............. III-85 B.Market Analytics..............III-88 Table 104: Rest of Europe Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-88

Table 105: Rest of Europe Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-89

Table 106: Rest of Europe 14-Year Perspective for Automated & Rapid Microbiological Tests by End-use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-90

5. ASIA-PACIFIC.............. III-91 A.Market Analysis.............. III-91 Current & Future Analysis..............III-91 Healthcare Spending in Asia-Pacific on the Rise III-91 India & China Offer Significant Growth Opportunities III-91 Table 107: China and India Lead Global Population (2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart) III-92

Table 108: Age-wise Breakup of China and India's Population Vis-à-vis Other Populous Countries Globally (2013) (includes corresponding Graph/Chart) III-93 Asia-Pacific - The Next Epicenter for the AIDS Epidemic III-93 B.Market Analytics..............III-94 Table 109: Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-94

Table 110: Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-95

Table 111: Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-96

Table 112: Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-97

Table 113: Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-98

Table 114: Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-99

5a. CHINA.............. III-100 A.Market Analysis.............. III-100 IVD Market - An Overview..............III-100 Table 115: Leading Players in the Chinese In-Vitro Diagnostics Market (2012): Percentage Breakdown of Value Sales for Abbott, Beckman/ Danaher, BioMerieux, DA AN, Hitachi, J&J, Mindray, Roche, Siemens, Sysmex and Others (includes corresponding Graph/Chart) III-100 Current & Future Analysis..............III-100 Strategic Corporate Development III-101 B.Market Analytics..............III-102 Table 116: Chinese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-102

Table 117: Chinese Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-103

Table 118: Chinese 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-104

5b. INDIA.............. III-105 A.Market Analysis.............. III-105 Current & Future Analysis..............III-105 Demand for Automated and Rapid Microbiology Testing Set to Grow in India.............. III-105 Growth Drivers.............. III-105 Automation - Name of the Game III-106 Strategic Corporate Development III-107 B.Market Analytics..............III-108 Table 119: Indian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-108

Table 120: Indian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-109

Table 121: Indian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-110

5c. REST OF ASIA-PACIFIC..............III-111 A.Market Analysis.............. III-111 Current & Future Analysis..............III-111 Strategic Corporate Development III-111 Cellabs Pty Ltd (Australia) - A Key Australian Player III-111 B.Market Analytics..............III-112 Table 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-112

Table 123: Rest of Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Syste
Read the full report: http://www.reportlinker.com/p04707098-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...



News published on and distributed by: